Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

Last updated: January 17, 2025
Sponsor: Darcy Krueger
Overall Status: Active - Recruiting

Phase

2

Condition

Epilepsy

Precancerous Condition

Neurofibromatosis

Treatment

Sirolimus

Placebo

Clinical Study ID

NCT05104983
2021-0438
1R01FD007275
  • Ages 1-6
  • All Genders

Study Summary

This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants.

This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. 0-6 months of age at the time of enrollment (subject must be <7 months ofchronological age at time of randomization and treatment initiation). Corrected agemust be at least 39 weeks (calculated by subtracting the number of weeks born before 40 weeks gestation from the chronological age).

  2. Has a confirmed diagnosis of TSC based on established clinical or genetic criteria

Exclusion

Exclusion Criteria:

  1. Prior history of seizures (clinical or electrographic) at the time of enrollment oridentified on baseline EEG.

  2. Has been treated in the past or is currently being treated at the time of enrollmentwith conventional anticonvulsant medications (AEDs), systemic (oral) mTOR inhibitors (such as rapamycin, sirolimus, or everolimus), ketogenic-related special diet, oranother anti-seizure therapeutic agent, device, or procedure.

  3. Has taken any other investigational drug as part of another research study, within 30 days prior to the baseline screening visit.

  4. Has a significant illness or active infection at the time of the baseline screeningvisit

  5. Has a history of significant prematurity, defined as gestational age <30 weeks atthe time of delivery, or other significant medical complications at birth or duringthe neonatal period that other than TSC would convey additional risk of seizures orneurodevelopmental delay (i.e. HIE, severe neonatal infection, major surgery,prolonged ventilatory or other life-saving supportive care or procedures).

  6. Abnormal laboratory values at baseline (i.e., renal function, liver function, orbone marrow production) that are in the opinion of the investigator clinicallysignificant and may jeopardize the safety of the study subject.

  7. Prior, planned or anticipated neurosurgery within 3 months of the baseline visit

  8. Has a TSC-associated condition for which mTOR treatment is clinically indicated (i.e. SEGA or AML).

  9. Subjects who are, in the opinion of the investigator, unable to comply with therequirements of the study.

Study Design

Total Participants: 64
Treatment Group(s): 2
Primary Treatment: Sirolimus
Phase: 2
Study Start date:
October 13, 2021
Estimated Completion Date:
June 30, 2027

Study Description

Tuberous Sclerosis Complex (TSC) is caused by genetic mutation in TSC1 or TSC2, resulting in dysregulation of the mechanistic target of rapamycin (mTOR) signaling pathway. Age at time of seizure onset in TSC infants has been linked to long-term neurodevelopmental outcome in this high-risk population. Sirolimus is an mTOR inhibitor used to treat many of the symptoms of TSC, including epilepsy. This will be the first study to truly evaluate a targeted, disease-modifying drug therapy for preventing or delaying seizure onset in TSC using a rational, mechanism-based therapeutic approach.

Connect with a study center

  • University of Alabama at Birmingham

    Birmingham, Alabama 35294
    United States

    Active - Recruiting

  • University of California at Los Angeles

    Los Angeles, California 90095
    United States

    Active - Recruiting

  • Stanford University

    Palo Alto, California 94304
    United States

    Active - Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado 80045
    United States

    Active - Recruiting

  • Lurie Children's Hospital of Chicago

    Chicago, Illinois 60611
    United States

    Active - Recruiting

  • Boston Children's Hospital

    Boston, Massachusetts 02115
    United States

    Active - Recruiting

  • Washington University -- St. Louis

    Saint Louis, Missouri 63110
    United States

    Active - Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina 27510
    United States

    Active - Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio 45229
    United States

    Active - Recruiting

  • University of Texas HSC at Houston

    Houston, Texas 77030
    United States

    Active - Recruiting

  • Seattle Children's Hospital

    Seattle, Washington 98105
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.